12:00 AM
Feb 07, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avonex: Phase III data; marketed to treat relapsing-remitting MS

An independent data monitoring committee recommended early termination of BGEN's 383-patient North American Phase III CHAMPS trial based on a statistically significant benefit of Avonex treatment in delaying development of MS in high-risk patients (those...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >